Navigation Links
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Date:6/11/2008

SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists. Full results of the study were presented here today during an oral presentation at the Annual European Congress of Rheumatology (EULAR).

The Phase 1/2 study evaluated multiple doses of tgAAC94 administered directly to affected joints with or without concurrent systemic TNF antagonist therapies. The study achieved its primary endpoint of safety and tolerability.

"We are encouraged by the patient-reported symptom improvement -- early signs of efficacy that indicate further study is warranted," said Philip Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, who presented the data.

Study Details

127 patients with inflammatory arthritis received a single intra-articular injection of either tgAAC94 or placebo, followed by a second injection 12-30 weeks later depending on when the injected joint met criteria for re-injection. tgAAC94 was well tolerated at all dose levels. Two SAEs of focused interest were reported -- a culture-negative septic arthritis considered probably related to study drug and a fatal disseminated histoplasmosis and retroperitoneal hemorrhage considered not related to study agent. Administration site reactions were observed in 12% of subjects.
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
2. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
3. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
4. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
5. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
6. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
10. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/sd9xxh/radiology ) ... Systems Market by Type, Deployment Mode, End User and ... report to their offering. The ... Million 2014, and is projected to reach $722.7 Million ... to 2019. The global radiology information ...
(Date:9/3/2015)... Sept. 3, 2015  Four financial reasons to ... white paper released by Leaf Healthcare, Inc . ... Research & Quality (AHRQ), pressure ulcers cost ... annually . In addition to direct treatment related ... penalties, and negatively impact hospital performance metrics. On ...
(Date:9/3/2015)... DUBLIN , Sept. 3, 2015 ... the addition of the "Investigation Report on ... offering. Thyroid hormones (TH) have ... babies or younger ones. Without thyroid hormones mainly ... and reproductive organs, even the growth hormone (GH) ...
Breaking Medicine Technology:Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 3Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3Investigation Report on China's Levothyroxine Market, 2010-2019 2
... Nov. 29, 2011 Uptake Medical® today announced the ... lung volume reduction in a patient with severe emphysema. ... endoscopic lung volume reduction system for the treatment of ... without leaving foreign materials in the lung. The patient ...
... IRVING, Texas, Nov. 29, 2011 A new study in ... has uncovered a novel mechanism that cancer cells may use ... "Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T ... Moffitt Cancer Center in Tampa, Fla., shows that a specific ...
Cached Medicine Technology:Uptake Medical Announces First Commercial Use of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces First Commercial Use of InterVapor for Patients With Severe Emphysema 3New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 2New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 3
(Date:9/3/2015)... ... September 03, 2015 , ... RealtyShares ... connecting accredited and institutional investors to real estate investment opportunities nationwide, today announced ... demand from both investors and sponsoring real estate companies. , These ...
(Date:9/3/2015)... ... September 03, 2015 , ... The Linda Hall ... the surface of a comet, the IceCube observatory at the South Pole, and the ... , The Fall Lecture Series for the world's foremost independently funded research library devoted ...
(Date:9/3/2015)... New York, New York (PRWEB) , ... September 03, 2015 , ... ... chief of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell ... Medical College. , Dr. Winchell is a nationally renowned expert in care for the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic ... virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this ... Scripts and Milliman, will discuss how plan sponsors are adopting bold, innovative strategies ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ProScrub is a ... back & forth, flicker, repeat, and custom speed effects without the use of keyframes. ... speed of effect. ProScrub tools are perfect complements to energetic video productions. ...
Breaking Medicine News(10 mins):Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... to release first quarter 2009 financial results on,Monday, May ... The Company will hold a conference call ... first quarter 2009 results. Listeners may access the ...
... Technology Used in Cimzia(R) Through Exclusive Nektar-UCB CollaborationSAN ... NKTR ) confirmed today UCB,s announcement ... has approved Cimzia(R) (certolizumab pegol), the only PEGylated ... of adult patients with moderately to severely active ...
... -- Treating a common heart rhythm disorder by burning ... drug treatments, a major international study has found. , ... 63 percent of patients with an irregular heartbeat called ... or symptoms. By comparison, only 17 percent of those ...
... Allscripts, Cisco, Citrix, Dell, Intel, Intuit, Microsoft Corp., ... U.S.CHICAGO, May 14 Allscripts today announced the ... who are partnering to educate 500,000 U.S. physicians ... Reinvestment Act (ARRA) of 2009. The Act ...
... Anpath Group, Inc. (OTC Bulleting Board: ANPG), ... (ESI) and its distributor partner, Minntech Japan Corporation, ... 36th annual meeting of the Japanese Society of ... meeting was attended by over 4,000 medical professionals. ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company ... patients, today announced its first quarter financial results for 2009. ... Food and Drug Administration (FDA) had placed all clinical studies ... a letter sent to Nile, and in a follow-up teleconference, ...
Cached Medicine News:Health News:BMP Sunstone To Report First Quarter 2009 Financial Results 2Health News:Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 2Health News:Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis 3Health News:Heating heart with catheter better than drugs for common heart rhythm disorder 2Health News:Heating heart with catheter better than drugs for common heart rhythm disorder 3Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 2Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 3Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 4Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 5Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 6Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 7Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 8Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 9Health News:Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records 10Health News:Anpath Group, Inc. Distributor Introduces Products at the Japanese Society of Intensive Care Medicine Annual Meeting 2Health News:Nile Therapeutics Reports 2009 First Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 First Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 First Quarter Financial Results 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: